![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 4
2022
Hofmann, Felix O. 
ORCID: https://orcid.org/0000-0002-6913-2429; Heinemann, Volker; D'Anastasi, Melvin; Gesenhues, Alena B.; Hesse, Nina; Weikersthal, Ludwig Fischer von; Decker, Thomas; Kiani, Alexander; Moehler, Markus; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Link, Hartmut; Modest, Dominik P.; Stintzing, Sebastian und Holch, Julian W.
(2022):
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3/AIO KRK-0306.
In: European Radiology, Bd. 33, Nr. 2: S. 1174-1184
[PDF, 2MB]
ORCID: https://orcid.org/0000-0002-6913-2429; Heinemann, Volker; D'Anastasi, Melvin; Gesenhues, Alena B.; Hesse, Nina; Weikersthal, Ludwig Fischer von; Decker, Thomas; Kiani, Alexander; Moehler, Markus; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Link, Hartmut; Modest, Dominik P.; Stintzing, Sebastian und Holch, Julian W.
(2022):
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3/AIO KRK-0306.
In: European Radiology, Bd. 33, Nr. 2: S. 1174-1184
[PDF, 2MB]
Fischer, Laura E. ORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2022):
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843
[PDF, 788kB]
ORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker
(2022):
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843
[PDF, 788kB]
2021
Liu, Lian; Erickson, Nicole Tonya; Ricard, Ingrid; Weikersthal, Ludwig Fischer von; Lerch, Markus M.; Decker, Thomas; Kiani, Alexander; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank; Scheithauer, Werner; Link, Hartmut; Hoeffkes, Heinz-Gert; Moehler, Markus; Gesenhues, Alena Britta; Theurich, Sebastian; Michl, Marlies; Modest, Dominik P.; Alguel, Hana; Stintzing, Sebastian; Heinemann, Volker und Holch, Julian W.
(2021):
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
In: International Journal of Cancer, Bd. 150, Nr. 1: S. 112-123
Stahler, Arndt; Heinemann, Volker; Schuster, Veronika; Heinrich, Kathrin; Kurreck, Annika; Giessen-Jung, Clemens; Weikersthal, Ludwig Fischer von; Kaiser, Florian; Decker, Thomas; Held, Swantje; Graeven, Ullrich; Schwaner, Ingo; Denzlinger, Claudio; Schenk, Michael; Neumann, Jens; Kirchner, Thomas; Jung, Andreas; Kumbrink, Jorg; Stintzing, Sebastian und Modest, Dominik P.
(2021):
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
In: European Journal of Cancer, Bd. 157: S. 71-80